Web Support for Weight-Loss Interventions: PREDIRCAM2 Clinical Trial Baseline Characteristics and Preliminary Results

Valeria Alcántara-Aragón, Susana Rodrigo-Cano, Ascension Lupianez-Barbero, María José Martinez, Carmen Martinez, José Tapia, José Manuel Iniesta, Susana Tenes, Eulalia Urgell, Gemma Navarro, M. Elena Hernando, Juan Francisco Merino-Torres, Alberto De Leiva, Cintia Gonzalez

Research output: Contribution to journalArticleResearchpeer-review

3 Citations (Scopus)


© Copyright 2018, Mary Ann Liebert, Inc. 2018. An ongoing clinical trial is testing the efficacy of web telematic support in a structured program for obesity treatment and diabetes prevention. Participants were recruited from two tertiary-care hospitals and randomized to receive either a telematic intervention (TI) supported by PREDIRCAM2 web platform or a non-telematic intervention (NTI). All receive 1-year follow-up. Both interventions consist of tailored dietary and exercise prescriptions, based on a Mediterranean dietary pattern and general WHO exercise recommendations for adults. At 6 months, both groups have received 7 contacts, 3 exclusively telematic for the TI group. This is a preliminary result intention-to-treat analysis. One hundred eighty-three participants were recruited, with a mean body mass index of 34.75 ± 2.75 kg/m2. General dropout rate at 6 months was 26.8%. Weight changes were statistically significant at months 3 and 6 compared to baseline, -2.915 ± 0.24 kg, -3.29 ± 0.36 kg, respectively (P < 0.001), but not statistically significant between the 3- and 6-month time points -0.37 ± 0.21 kg (P = 0.24). Mean group differences showed that the TI group lost 1.61 ± 1.88 kg more than the NTI group (P = 0.39). Waist, waist/hip ratio, resting heart rate, blood pressure, HbA1c, and low-density lipoprotein cholesterol also showed statistically significant changes at 6 months, with no significant differences between groups. Weight loss in the TI group shows similar results as the usual care NTI group for weight loss and control of obesity comorbidities. At completion of the clinical trial, these results will be reevaluated to assess the potential role of web support in weight-loss maintenance and its cost-effectiveness.
Original languageEnglish
Pages (from-to)380-385
JournalDiabetes Technology and Therapeutics
Issue number5
Publication statusPublished - 1 May 2018


  • Lifestyle modification.
  • Metabolic syndrome
  • Obesity
  • Telemedicine


Dive into the research topics of 'Web Support for Weight-Loss Interventions: PREDIRCAM2 Clinical Trial Baseline Characteristics and Preliminary Results'. Together they form a unique fingerprint.

Cite this